Approaches to rheumatoid arthritis in 2000

Area of Science:

• Rheumatology
• Clinical Pharmacology
• Inflammation Research

Background:

• Tumor necrosis factor (TNF) inhibition achieved significant success by 2000, yet its high cost and adverse effects were under-investigated.
• Leflunomide gained status as a disease-modifying antirheumatic drug (DMARD).
• Cyclooxygenase-2 (Cox-2) inhibitors offered improved gastrointestinal tolerance but posed risks of thromboembolism.

Purpose of the Study:

• To review the therapeutic landscape of rheumatic diseases around the year 2000.
• To highlight emerging concerns regarding the risks and adverse effects of new therapies.
• To discuss the influence of genetic factors and inflammation on disease pathogenesis and outcomes.

Main Methods:

• Literature review of clinical and epidemiological studies published around the year 2000.
• Analysis of therapeutic successes, limitations, and emerging safety concerns.
• Examination of genetic associations and inflammatory mechanisms in rheumatic diseases.

Main Results:

• TNF inhibition was a cornerstone therapy, but cost and safety data were limited.
• Cox-2 inhibitors showed promise for gastrointestinal safety but carried thromboembolic risks.
• Genetic polymorphisms in TNF, mannose-binding lectin, and gamma-interferon were linked to disease susceptibility and severity.
• Chronic inflammation in rheumatic diseases was implicated as a risk factor for accelerated atherosclerosis.

Conclusions:

• The early 2000s marked a period of therapeutic advancement in rheumatology, balanced by the need to address cost and safety concerns.
• Further research was needed to fully understand the risks associated with TNF inhibitors and Cox-2 inhibitors.
• Genetic and inflammatory pathways presented complex targets for future therapeutic strategies.